Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Aug 1;96(8):E269-E272.
doi: 10.1002/ajh.26201. Epub 2021 May 3.

Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials

Fortunato Morabito  1   2 , Giovanni Tripepi  3 , Giovanni Del Poeta  4 , Francesca Romana Mauro  5 , Gianluigi Reda  6 , Paolo Sportoletti  7 , Luca Laurenti  8 , Marta Coscia  9 , Yair Herishanu  10 , Sabrina Bossio  1 , Marzia Varettoni  11 , Roberta Murru  12 , Annalisa Chiarenza  13 , Andrea Visentin  14 , Adalgisa Condoluci  15 , Riccardo Moia  16 , Daniela Pietrasanta  17 , Giacomo Loseto  18 , Ugo Consoli  19 , Ilaria Scortechini  20 , Francesca Maria Rossi  21 , Antonella Zucchetto  21 , Hamdi Al-Janazreh  2 , Ernesto Vigna  22 , Enrica Antonia Martino  22 , Ramona Cassin  6 , Graziella D Arrigo  3 , Sara Galimberti  23 , Angela Rago  24 , Ilaria Angeletti  25 , Annalisa Biagi  5 , Ilaria Del Giudice  5 , Riccardo Bomben  22 , Antonino Neri  6 , Gilberto Fronza  26 , Paola Monti  26 , Paola Menichini  26 , Jacopo Olivieri  27 , Giovanna Cutrona  28 , Davide Rossi  15 , Antonio Cuneo  29 , Francesco Di Raimondo  13 , Gianluca Gaidano  16 , Aaron Polliack  30 , Livio Trentin  14 , Robin Foà  5 , Manlio Ferrarini  31 , Valter Gattei  21 , Massimo Gentile  22
Affiliations
Free article
Editorial

Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials

Fortunato Morabito et al. Am J Hematol. .
Free article
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425-2437.
    1. Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432-443.
    1. Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517-2528.
    1. Morabito F, Gentile M, Monti P, et al. TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors. Expert Opin Investig Drugs. 2020;29(8):869-880.
    1. Gentile M, Morabito F, Del Poeta G, et al. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. Leukemia. 2021;35(1):235-238.

Publication types

MeSH terms